novo nordisk glp-1 asks FDA to prevent compounders from making knockoffs Novo Nordisk CEO explains why

Firmly apply to your skin and wear for 8 hours

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

CBO projects that net federal spending would increase around $35.5 billion between 2026 and 2034 and would continue to increase through 2044.

Discover the mechanisms and uses of GLP-1 agonist drugs, including their role in the treatment of type 2 diabetes and weight loss.

Even though India prohibits direct-to-consumer marketing of prescription drugs, regulators are watching out for messaging to induce misuse